BACKGROUND: Activated vitamin D analog, paricalcitol, has been shown to attenuate the development of cardiac hypertrophy in Dahl salt sensitive (DSS) rats. To determine whether an antihypertrophic effect is class specific, we tested if doxercalciferol (a pro-hormone vitamin D2 analog) could also attenuate the development of cardiac hypertrophy in DSS rats. METHODS AND RESULTS: Male DSS rats were fed a high salt (HS) diet for 6 weeks beginning at 6 weeks of age. Doxercalciferol was administered intraperitoneally at 150 ng, 3 times per week (Monday, Wednesday, Friday) for 6 weeks. Pathological and echocardiographic findings demonstrated that rats on HS diet with doxercalciferol administration had significant decrease in cardiac hypertrophy and improved cardiac function compared to the HS + vehicle. In addition, there was a significant decrease in plasma brain natriuretic peptide (BNP) level and tissue atrial natriuretic factor (ANF) mRNA level with doxercalciferol treatment. Doxercalciferol also significantly reduced the level of protein kinase C-α (PKCα) suggesting that PKC-mediated cardiac hypertrophy may be associated with vitamin D deficiency. CONCLUSIONS: Administration of doxercalciferol attenuated the development of HS diet induced cardiac hypertrophy and cardiac dysfunction in DSS rats.
BACKGROUND: Activated vitamin D analog, paricalcitol, has been shown to attenuate the development of cardiac hypertrophy in Dahl salt sensitive (DSS) rats. To determine whether an antihypertrophic effect is class specific, we tested if doxercalciferol (a pro-hormone vitamin D2 analog) could also attenuate the development of cardiac hypertrophy in DSSrats. METHODS AND RESULTS: Male DSSrats were fed a high salt (HS) diet for 6 weeks beginning at 6 weeks of age. Doxercalciferol was administered intraperitoneally at 150 ng, 3 times per week (Monday, Wednesday, Friday) for 6 weeks. Pathological and echocardiographic findings demonstrated that rats on HS diet with doxercalciferol administration had significant decrease in cardiac hypertrophy and improved cardiac function compared to the HS + vehicle. In addition, there was a significant decrease in plasma brain natriuretic peptide (BNP) level and tissue atrial natriuretic factor (ANF) mRNA level with doxercalciferol treatment. Doxercalciferol also significantly reduced the level of protein kinase C-α (PKCα) suggesting that PKC-mediated cardiac hypertrophy may be associated with vitamin D deficiency. CONCLUSIONS: Administration of doxercalciferol attenuated the development of HS diet induced cardiac hypertrophy and cardiac dysfunction in DSSrats.
Authors: Ming Teng; Myles Wolf; Edmund Lowrie; Norma Ofsthun; J Michael Lazarus; Ravi Thadhani Journal: N Engl J Med Date: 2003-07-31 Impact factor: 91.245
Authors: Sangita Choudhury; Soochan Bae; Sheetal R Kumar; Qingen Ke; Bhargavi Yalamarti; Jun H Choi; Lorrie A Kirshenbaum; Peter M Kang Journal: Cardiovasc Res Date: 2010-01-01 Impact factor: 10.787
Authors: Natalya Bodyak; Juan Carlos Ayus; Steven Achinger; Venkatesha Shivalingappa; Qingen Ke; Yee-Shiuan Chen; Debra L Rigor; Isaac Stillman; Hector Tamez; Paul E Kroeger; Ruth R Wu-Wong; S Ananth Karumanchi; Ravi Thadhani; Peter M Kang Journal: Proc Natl Acad Sci U S A Date: 2007-10-17 Impact factor: 11.205
Authors: Songcang Chen; Denis J Glenn; Wei Ni; Christopher L Grigsby; Keith Olsen; Minobu Nishimoto; Christopher S Law; David G Gardner Journal: Hypertension Date: 2008-10-20 Impact factor: 10.190
Authors: Nonanzit Pérez-Hernández; Gad Aptilon-Duque; María Cristina Nostroza-Hernández; Gilberto Vargas-Alarcón; José Manuel Rodríguez-Pérez; Ruben Blachman-Braun Journal: Korean J Intern Med Date: 2016-04-27 Impact factor: 2.884
Authors: Raffaele Altara; Fouad A Zouein; Rita Dias Brandão; Saeed N Bajestani; Alessandro Cataliotti; George W Booz Journal: Front Cardiovasc Med Date: 2018-02-21